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EDITORIAL
High-Sensitivity C-Reactive Protein in Transcatheter Aortic Valve Implantation
Prognostic Biomarker and New Potential Therapeutic Avenue
Cécile Oury, PhDa, Christophe Martinez, MDa, and Patrizio Lancellotti, MD, PhDa,b
aGIGA Cardiovascular Sciences, Heart Valve Clinic, Department of Cardiology, University of Liège Hospital, University Hospital Sart Tilman, Liège,
Belgium; bGruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy
The introduction of transcatheter aortic valve implantation
(TAVI) offered a new therapy to patients with severe aortic
stenosis who are not candidates for surgical valve replacement
(SAVR)1,2 or who are at high risk for complications due to
surgery.3 TAVI has proven to be similar to SAVR with respect
to disabling stroke or death in patients at intermediate clinical
risk.4 A recent report from the PARTNER 3 trial indicates
that, in patients at low surgical risk, the rate of the composite
of death, stroke, or rehospitalization at 1 year was significantly
lower with TAVI than with SAVR.5 As TAVI procedure
became more routinized and device technology was refined,
near-term survival after TAVI improved substantially during
the last years. According to a systematic assessment of evi-
dence among 145 studies performed between 2007 and 2016,
it appeared that risk-adjusted 30-day and 1-year mortality
rates decreased from 10.48% to 2.27% and from 30.24% to
11.35% over time, respectively.6 In a study analyzing the
mortality rate in 6,420 patients undergoing TAVI (UK regis-
try) compared to a matched general population, it was found
that relative survival after TAVI was high, corresponding to
95.4%, 90.2%, and 83.8% at 30 days, 1 year, and 3 years,
respectively.7 Increasing age was associated with significantly
lower excess hazards after TAVI, with survival rates in
patients ages > 85 years approximated those of a matched
general population within 3 years. In view of current evolu-
tion, it is thus very likely that TAVI will progressively sup-
plant SAVR for AS patients who are eligible for both
procedures. Even though a decline of post-TAVI mortality
has been acknowledged, the risk remains relatively high for
certain yet unidentified patient populations. Data from the
international CENTER collaboration study (10,982 patients
undergoing transfemoral TAVI) indicate a 30-day risk of
stroke of 2.4% after TAVI, which was responsible for
a 6-fold increase of 30-day mortality.8 Independent predictors
of stroke were previous cerebrovascular events and renal
insufficiency. Strikingly, this study showed that stroke rate
did not decline from the early years of TAVI procedures to
more recent years. In addition, several studies indicate that
the risk of stroke is higher at extended follow-up, with
reported rates reaching up to 10.6% at 1-year post-TAVI
(reviewed in.9) Thus, stroke remains the most devastating
complication of TAVI. Since the prognosis of patients who
benefit the most from TAVI is likely not only determined by
AS severity, but also by multiple comorbidities, and possibly
by the extent of extravalvular cardiac damage,10 biomarkers
that would implement clinical scores to identify patients at
risk of major cardiovascular events, including stroke, or death
could be very useful. Importantly, although valve replacement
clearly improves patient outcome,11,12 baseline comorbidities
if left sub-optimally treated or myocardial damage might
indeed, in specific cases, be the main cause of poor outcome.
Several small size studies indicate that circulating biomarkers
of myocardial injury, cardiac mechanical stretch, inflamma-
tion or hemostasis may predict TAVI-associated complica-
tions and mortality.13 However, none of these biomarkers
have already been implemented in clinical practice, as their
role needs to be validated in larger studies. Therefore, the
identification of easily accessible pre-procedural circulating
biomarkers that would reflect patient risk in a more persona-
lized manner should become a priority.
In this issue, Ungjeong et al.14 assessed the predictive value
of pre-procedural high-sensitivity CRP levels (hsCRP) with
respect to 1-year disabling stroke or all-cause mortality in
patients who underwent TAVI at the Asian Medical Center
(Seoul, Korea) between 2010 and 2017. A total of 243 patients
were included. Disabling stroke was defined as a score of at
least 2 on the modified Rankin scale at 90 days after the index
clinical event. All outcomes were defined according to the
Valve Academic Research Consortium-2 criteria.15 About
26% of the patient population had elevated CRP levels
(≥3 mg/L) at baseline. These patients had a higher Society of
Thoracic Surgery (STS) score and EuroSCORE, they had more
frequent end stage renal disease, and they had lower ejection
fraction than those with nonelevated CRP. Strikingly, patients
with elevated CRP levels did not have more severe AS. About
16.7% of the patients in the elevated CRP group died or
presented disabling stroke compared to 5.5% patients in the
nonelevated CRP group. hsCRP ≥3 mg/L was associated with
a 3-fold higher risk of composite outcome. Adding the infor-
mation of CRP elevation to STS score or EuroSCORE signifi-
cantly improved risk prediction, especially when considering
disabling stroke. Neither brain natriuretic peptide nor tropo-
nin I levels were significantly associated with TAVI composite
outcome, and adding them to CRP in the multivariable model
did not improve risk prediction. The authors concluded that
pre-procedural hsCRP measurements might be implemented
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in risk prediction scores for TAVI. If validated in larger
multicenter studies, measuring pre-procedural hsCRP levels
with standardized immunoassays might have important prog-
nostic value to evaluate the risk of disabling stroke, a major
complication of TAVI. In agreement with the study by
Ungjeong et al., previous work already suggested that inflam-
mation could be important in predicting outcome of TAVI
patients. For instance, the study by Kim et al. described
a worse 1-year survival for TAVI patients with baseline
hsCRP levels >2 mg/L.16 In this sudy, pre-procedural inflam-
mation, evaluated by levels of growth differentiation 15 (GDF-
15), also seemed to be implicated in a lack of post-TAVI
ventricular recovery, as assessed by global longitudinal strain
(GLS) at 1-year follow-up. Furthermore, GLS at 1 month
predicted 1-year mortality. Beside different CRP threshold
between the two studies, it could have been informative to
know the effect of pre-procedural CRP levels on ventricular
function during follow-up of patients from the study of
Ungjeong et al. Patients with elevated CRP levels had indeed
lower ejection fraction, depicting potential link of hsCRP
levels with cardiac damage. This analysis could also have
clarified the role of inflammatory processes in potentially
adverse post-procedural ventricular remodelling.
Notwithstanding, the findings of Ungjeong et al. might pave
the way toward new inflammation targeted therapies that
could improve risk stratification and long-term survival in
TAVI. Indeed, upon acute tissue injury or inflammation,
CRP is produced by the liver in response to elevation of pro-
inflammatory cytokines such as IL-6, IL-1β, and TGF-β,
which therefore represent the main CRP triggers. In acute
coronary syndrome (ACS) patients, several studies have been
conducted with the aim to determine if targeting these cyto-
kines with available drugs could reduce the inflammatory
response at the time of ACS, and subsequent events. The
rationale of these studies comes from proven association
between hsCRP levels and the occurrence of major cardiovas-
cular events or death in patients who experienced a previous
ACS. In a secondary analysis of the Vascular Inflammation
Suppression to Treat Acute Coronary Syndromes for
16 Weeks (VISTA-16),17 the initial and subsequent increases
in hsCRP levels during 16 weeks after ACS were associated
with a greater risk of the combined major cardiovascular
event end point (composite of cardiovascular death, myocar-
dial infarction, nonfatal stroke, or unstable angina with docu-
mented ischemia requiring hospitalization), cardiovascular
death, and all-cause death despite optimized medical thera-
pies. The randomized double-blind Canakinumab Anti-
Inflammatory Thrombosis Outcomes Study (CANTOS) trial
tested the effect of canakinumab, a therapeutic monoclonal
antibody targeting the inflammatory cytokine interleukin-1β
in patients with previous myocardial infarction and CRP
≥2 mg/L, the primary endpoint efficacy being nonfatal myo-
cardial infarction, nonfatal stroke, or cardiovascular death.18
It was found that patients for whom CRP level decreased from
baseline with such treatment had a more favorable prognosis
than those with CRP levels that remained elevated. Treatment
with Canakinumab led to a significantly lower rate of recur-
rent cardiovascular events than placebo, independent of lipid-
level lowering. Whether these treatments can prevent adverse
left ventricular remodeling post-MI is currently unknown.
It should be noted that, in Ungjeong et al.’s study, patients
with elevated hsCRP had more severe atherosclerosis or cal-
cification in thoracic aorta. However, this variable did not
independently predict composite outcome at 1 year, which is
in contrast with post-procedure new-onset atrial fibrillation.
This observation might corroborate the data from the
CENTER collaboration study showing that patients with
stroke had more frequently documented new-onset atrial
fibrillation.7
Similarly, as in the VISTA-16 study on ACS patients,17 it
would be interesting to determine if, in addition to initial
hsCRP level, serial monitoring of hsCRP levels post-TAVI
could further help identify patients at greater risk of post-
procedural cardiovascular events or death, both on the short
and long term. In TAVI patients, it remains to be determined
whether hsCRP level represents a surrogate marker of inflam-
mation or whether it should be considered as a direct biolo-
gical target. In the latter case, interventions targeted to lower
pre-procedural CRP levels might then be beneficial to reduce
morbidity or mortality rate post-TAVI independently of
established background therapies. It also remains to be deter-
mined if IL-1β levels or levels of other cytokines that may
drive increases in CRP, for example, IL-6, TGF-β, TNF-β,
INF-γare elevated in patients with severe aortic stenosis
undergoing TAVI and whether these cytokines may predict
outcome or may be associated with AS severity or stages of
extravalvular cardiac damage.
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